The membrane attack complex as an inflammatory trigger
Abstract
The final common pathway of all routes of complement activation involves the non-enzymatic assembly of a complex comprising newly formed C5b with the plasma proteins C6, C7, C8 and C9. When assembly occurs on a target cell membrane the forming complex inserts into and through the bilayer to create a pore, the membrane attack complex (MAC). On some targets, pore formation causes rapid lytic destruction; however, most nucleated cell targets resist lysis through a combination of ion pumps, membrane regulators and active recovery processes. Cells survive but not without consequence. The MAC pore causes ion fluxes and directly or indirectly impacts several important signalling pathways that in turn activate a diverse series of events in the cell, many of which are highly pro-inflammatory. Although this non-lytic, pro-inflammatory role of MAC has been recognised for thirty years, no consensus signalling pathway has emerged. Recent work, summarised here, has implicated specific signalling routes and, in some cells, inflammasome involvement, opening the door to novel approaches to therapy in complement-driven pathologies.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Sublytic levels of MAC have been shown to stimulate the release of growth factors from nucleated cells, including VEGF from RPE in cell culture studies.
“For example, sublytic levels of MAC have been shown to stimulate the release of growth factors from nucleated cells [99,100], including VEGF from RPE in cell culture studies [146,165].”
From Bruch’s Membrane: A Key Consideration with Complement-Based Therapies for Age-Related Macular Degeneration (2023) · cites this paper as [100]
The citation lists haven’t been fetched yet
References 46 · Cited by 205
- Authors
- Morgan, B. P.
- Affiliations
- Cardiff University (GB)
- Corresponding author
- Morgan, B. Paul
- ORCID
- Morgan, B. Paul
- Venue
- Immunobiology
- Publisher
- Elsevier BV
- Published
- 2016-06
- Volume
- 221
- Issue
- 6
- Pages
- 747-751
- ISSN
- 0171-2985 (ISSN-L)
- OpenAlex
- W1999967353
- Cited by
- 205
- References
- 46
- Citations by year
- 2026: 13 · 2025: 19 · 2024: 10 · 2023: 27 · 2022: 20 · 2021: 25 · 2020: 22 · 2019: 16 · 2018: 20 · 2017: 11 · 2016: 15 · 2015: 7
- FWCI
- 1.67
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Immunobiology (publishedVersion)
- PubMed (publishedVersion)
- ORCA Online Research @Cardiff (Cardiff University) (submittedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Complement system in diseases
- Life Sciences › Immunology and Microbiology › Immunology › Biomarkers in Disease Mechanisms
- Health Sciences › Medicine › Genetics › Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Keywords
- membrane attack complex, complement activation, pro-inflammatory signaling, ion flux, pore formation, cell membrane damage, inflammasome, complement inhibition therapy
- MeSH terms
- Animals, Complement System Proteins, Complement Activation, Humans, Inflammation, Signal Transduction, Complement Membrane Attack Complex, Ion Pumps, Pore Forming Cytotoxic Proteins, Inflammasomes
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review